Brokerages Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Price Target at $12.00

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been assigned an average rating of “Hold” from the six analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $12.00.

Several research analysts recently issued reports on the stock. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Barclays boosted their target price on shares of Xeris Biopharma from $9.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, August 20th.

Xeris Biopharma Trading Down 1.4%

XERS stock opened at $8.48 on Thursday. The business has a fifty day moving average price of $8.29 and a 200 day moving average price of $6.93. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. Xeris Biopharma has a fifty-two week low of $5.25 and a fifty-two week high of $10.08. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -77.09 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The business had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. Analysts expect that Xeris Biopharma will post 0.07 EPS for the current fiscal year.

Insider Activity at Xeris Biopharma

In other news, insider Steven Pieper sold 5,000 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $8.50, for a total transaction of $42,500.00. Following the completion of the sale, the insider owned 1,361,053 shares in the company, valued at $11,568,950.50. The trade was a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $8.01, for a total value of $133,494.66. Following the transaction, the insider directly owned 1,144,462 shares in the company, valued at $9,167,140.62. This trade represents a 1.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 271,499 shares of company stock valued at $2,038,917 over the last quarter. 4.35% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Xeris Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of XERS. Kestra Advisory Services LLC acquired a new stake in Xeris Biopharma during the 4th quarter worth $25,000. KBC Group NV acquired a new position in shares of Xeris Biopharma in the 1st quarter valued at $27,000. Allworth Financial LP acquired a new position in shares of Xeris Biopharma in the 2nd quarter valued at $34,000. State of Wyoming bought a new position in shares of Xeris Biopharma in the 2nd quarter worth $52,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in shares of Xeris Biopharma by 9,276.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after purchasing an additional 7,421 shares during the last quarter. 42.75% of the stock is owned by institutional investors.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.